Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06764485 · ClinicalTrials.gov registry record · Phase 3

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Celgene.

Recruiting
Registry status
Phase 3
Development phase
960
Enrollment target
20
Study locations

NCT06764485 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Celgene. The registered enrollment target is 960 participants, above the 184-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (422% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06764485, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 3
Development phase
960 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Enzalutamide
  • DRUG Abiraterone
  • DRUG BMS-986365
  • DRUG Predinsone/Prednisolone

Study Locations (20)

California

  • Los Angeles Cancer Network (LACN) - Anaheim
  • Moores Cancer Center - La Jolla
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • Local Institution - 0364 - Los Angeles
  • Pacific Hematology Oncology Associates - San Francisco
  • San Francisco VA Health Care System - San Francisco

Colorado

  • Rocky Mountain Regional VA Medical Center - Aurora
  • Rocky Mountain Cancer Centers, LLP - Denver
  • Colorado Clinical Research - Lakewood

Maryland

  • Chesapeake Urology - Baltimore
  • Johns Hopkins Hospital - Baltimore
  • James M Stockman Cancer Institute - Frederick

Kansas

  • The University of Kansas Cancer Center - Westwood - Westwood
  • Wichita Urology Group - Wichita

Alabama

  • Central Alabama Research - Birmingham

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Florida

  • Lakeland Regional Cancer Center - Lakeland

Trial Details

FieldValue
Enrollment Target 960 participants
Start Date 2025-03-13
Est. Completion 2029-01-19
Phase Phase 3

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06764485

The ClinicalTrials.gov registry entry for NCT06764485 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (422% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.

NCT06764485 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Maryland.

Frequently Asked Questions

What is clinical trial NCT06764485 about?

NCT06764485 is a clinical study titled "A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

What is the current status of trial NCT06764485?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2025-03-13. Estimated completion is 2029-01-19.

What conditions does trial NCT06764485 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06764485?

The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), BMS-986365 (DRUG), Predinsone/Prednisolone (DRUG).

Who is sponsoring clinical trial NCT06764485?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06764485 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.